The Supreme Court dismissed convictions of 2 doctors accused of overprescribing opioids, moving the cases to lower courts; Cabinet secretaries met with 14 insurers and payer groups to push for contraceptive coverage without co-pays; the FDA may upgrade COVID-19 boosters to target newer subvariants.
As reported by The Washington Post, the Supreme Court dismissed the convictions of 2 doctors accused of overprescribing opioids and operating opioid “pill mills.” The 2 physicians, Xiulu Ruan and Shakeel Kahn, were each originally sentenced to more than 20 years in prison for unlawfully dispensing and distributing prescription drugs. The Supreme Court rejected federal request to affirm the convictions and unanimously agreed to let lower courts review them further, claiming there was not enough evidence to prove beyond reasonable doubt that the physicians knew or intended to prescribe drugs in an unauthorized way.
Following Supreme Court Justice Clarence Thomas’ concurring opinion in the Dobbs v Jackson Women's Health Organization decision released Friday, in which he suggested the right to contraception should be reconsidered, HHS Secretary Xavier Becerra and Department of Labor Secretary Marty Walsh met with 14 major health insurers and payer groups to push for contraceptive coverage with no cost to their enrollees, Politico reported. Some of these insurers included Anthem, Blue Cross Blue Shield Association, CVS Health Humana, Kaiser Permanente, Optum, and United Health. Under the Affordable Care Act, payers must cover at least 1 form of contraceptive for each FDA-approved method without co-pay, and the Cabinet secretaries are working to ensure these groups are complying.
An independent advisory panel to the FDA is set to announce today whether an updated COVID-19 booster vaccines is needed to target newer strains, The New York Times reported. If recommended, these vaccines will become available in fall 2022. However, they will require laboratory and animal testing since the virus is evolving before human trials can be concluded. Experts also argue that a new vaccine should target the most recent subvariants BA.4 and BA.5, not just the Omicron strain.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines
September 6th 2025National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American College of Chest Physicians (CHEST) offer complementary yet distinct frameworks for lung cancer care, reflecting differences in evidence evaluation, regional adaptation, and policy integration.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More